Published in Blood Weekly, December 18th, 2003
This follows the announcement by Jerini in January that the European Agency for the Evaluation of Medicinal Products had granted orphan drug designation to Icatibant for the same indication. Jerini will file an investigational new drug application (IND) for Icatibant in this indication with the U.S. FDA. Regulatory approvals for the IND are expected for March 2004. Jerini is currently conducting an open phase II...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.